纵向血浆代谢组学指导食管鳞状细胞癌化疗免疫治疗的动态风险评估与饮食调节
Longitudinal Plasma Metabolomics Guides Dynamic Risk Assessment and Dietary Modulation for Esophageal Squamous Cell Cancer Chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
食管癌的免疫联合治疗
英文原题：Immune-based combination therapy for esophageal cancer.
查看英文原题
Immune-based combination therapy for esophageal cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
食管癌（EC）是一种侵袭性恶性肿瘤，在全球范围内引起医疗关注。标准治疗方案包括手术切除、化疗、放疗和靶向分子治疗。EC 所有分期的五年生存率约为 20%，范围为 5% 至 47%，治疗后复发率高且预后差。免疫疗法在多种恶性肿瘤中显示出优于传统疗法的疗效和耐受性。EC 的免疫疗法，包括免疫检查点抑制剂、癌症疫苗和过继细胞疗法，已显示出临床优势。特别是针对 PD-1 的单克隆抗体在联合治疗中具有令人满意的作用，并被推荐用于一线或二线治疗。在此，我们对基于免疫疗法的 EC 联合治疗进行了系统性总结和分析。
展开英文摘要原文
Esophageal cancer (EC) is an aggressive malignancy raising a healthcare concern worldwide. Standard treatment options include surgical resection, chemotherapy, radiation therapy, and targeted molecular therapy. The five-year survival rate for all stages of EC is approximately 20%, ranging from 5% to 47%, with a high recurrence rate and poor prognosis after treatment.
Immunotherapy has shown better efficacy and tolerance than conventional therapies for several malignancies. Immunotherapy of EC, including immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapy, has shown clinical advantages. In particular, monoclonal antibodies against PD-1 have a satisfactory role in combination therapy and are recommended for first- or second-line treatments.
Here, we present a systematic summary and analysis of immunotherapy-based combination therapies for EC.
论文信息
- 作者
- Wang H、Xu Y、Zuo F、Liu J、Yang J
- 单位
- Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu,  China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 36591219 · DOI 10.3389/fimmu.2022.1020290
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →